MEET THE EXPERTS | Ethical Fashion Forum
EXPO · 3. EXCELLENCE Excellence events bring together the foremost experts in the ethical fashion field to develop resources, deliver training and offer one to one MEET THE EXPERT sessions. Scroll down to see. Susan Perry Williams () Meet the Experts. () Corporate Governance Research in Accounting and Auditing: Insights, Practice Implications, and Future . STEPS Meet-the-Expert Session opens for new applications Piloted in , STEPS will celebrate its 9th Anniversary in January at the 16th ESOU.
Meet the Experts: Interview with Professor Raphael Mechoulam
Currently, physicians can recommend medical cannabis for patients who suffer from a symptom or a disease that is included on the list of approved indications; the Ministry of Health regularly reviews this list, and cautiously considers including more diseases, mainly ones with mental symptoms.
So there is still a way to go — because according to previous studies, some of which I contributed to, it is plausible that other patients may benefit medically from using cannabis. What do you think is obstructing progress? There are still quite a few problems.
- Our events
- Selection and sizing tool
- MARKET AND SALES
I am a chemist, and so my point of view is exclusively scientific. From a chemist's perspective, there is no such thing as "medical cannabis", because this is something that is not standardized. It is not a medicine. We need to have very well defined products so we can specify which cannabinoids are better for which indications, and what the right dosages are, and side effects of course. I believe this is the only way to allow more patients to benefit medically from cannabis.
We also know that sativa strains differ from indica strains. In Israel, instead of having a variety of strains, the regulatory plan is to have just a few types of cannabis that will be standardized more strictly. The current standardization does not match the medical standards closely enough.
And the strains that licensed growers are currently dispensing to patients are not typified or standardized enough. And most of them have weird names, by the way. What other concerns do you have aside from standardization?
There is a lack of clinical research, and that is the other side of the same coin. The regulations are still restricting research on cannabis. More and more evidence is accumulating, but certainly not enough yet.
BBC One - Talk to the Animals - Meet the experts from episode 2
So many cancer patients around the world have used cannabis for years, but still there is not even one randomized-controlled clinical trial with cancer patients. Every medication goes through clinical trials. And clinical trials cost money, usually quite a lot. The funding is another big issue.
Clinical trials are usually funded by pharmaceutical companies, but it seems that those companies are not interested in investing in cannabis. Since it cannot be patented, they would probably not get a return on their money. How do you think more such trials can be promoted? Clinicians in Israel, whom I collaborate with, have found ways to facilitate studies; some received grants, donations or other contributions. Thus, there are already more clinical trials that are currently in progress.
For example, a preliminary study on CBD for the prevention and treatment of GvHD1 had very good results, and now they are doing the second trial with more patients. So in the future I see no reason for cannabidiol not being a first-line treatment for GvHD. And this is only one example, and it is quite exciting actually. There is still a long way to go, but I feel that we are going in the right direction.
When you say that cannabidiol might be a treatment in the future, do you mean herbal canabidiol or a synthetic one?
Whether it is derived from herbal cannabis or synthetic — they should be the same compound. In the lab, cannabidiol is easy to work with, and it can be isolated from herbal cannabis to a level of total purity.
But it might as well be synthetic. It may very well be that other cannabinoids can provide therapeutic benefits. Those molecules have low stability, and as a result, very little research has been done on them. But I think that they have a big potential and should be studied more.
Meet the expert: Sensor | Grundfos
How do you see the situation 5 years from now? And 10 years from now? I think that the products will be better analyzed and standardized, and hopefully there will be more clinical evidence. We will know more about the "entourage effect". But if we look at the pharmaceutical markets and how medications evolve, I also think that the situation will be very different than it is today.
We cannot use penicillin, but only derivatives of it. It may take more than 5 years, but the situation will probably be the same with cannabinoids. Design Friendship take a strategic approach to design and marketing, working with businesses on every aspect of their branding and media from print to logo and online presence.
Their involvement has increased profile and brand appeal for scores of businesses. If you want to increase the impact of your brand, or launch a new one, Nat is the person to talk to. Press, media and social networking Amisha is the mastermind behind the Ethical Fashion Network, which has a current growth rate of new members every week. As founder and director of Amisha jewellery, Amisha has years of experience and has achieved considerable success in the promotion of design led product through press, media and social networking channels- on a restricted budget.
She was also production manager for the RE: Fashion Awards, the worlds leading ethical fashion award event, and played an overall strategic role with EFF. Amisha now works with fashion brands helping them understand the complete picture when it comes to bringing sustainability into their businesses, and advising them on how to increase their presence in the media and on-line. If you want to run successful events in the ethical fashion sector- and learn how to build a campaign that will make sure they are packed- speak to Emily.
BUSINESS Introduce your business or project and get tailored feedback specific to your needs or seek advice on overall strategy, finance and funding for ethical fashion business- including grant funding, social investment, sponsorship and how to access it, success through partners and patrons, and legal issues.
Ethical Fashion Business- Overall business strategy, sourcing, finance and funding Tamsin is Founder and Managing Director of the Ethical Fashon Forum and has over 10 years of experience in the ethical fashion business sector. In she founded fair trade fashion label juste. She has secured partnerships with leading multinationals, fashion bodies and global institutions such as the UN. As Founder of the Ethical Fashion Consultancy, Tamsin has worked with hundreds of pioneering entrepreneurs and fashion businesses in the ethical fashion sector on every aspect of business strategy.
Dont miss out on this rare opportunity for a one to one session with Tamsin. The following four years he worked on behalf of Private Equity firms, Business angels and boards in Asia working within the SME turnaround market in multiple sectors.
Creating designer clothing from reclaimed fabrics they epitomise what can be acheived through upcycling. Nin is a successful- designer entrepreneur who has built her brand from scratch, achieved widespread press coverage, growing sales and groundbreaking retail partnerships for Goodone, without significant start up funding.
She can offer valuable advice on how to make the most of opportunities and avoid the pitfalls relating to every aspect of ethical fashion business start up, marketing, management and growth. In December a new recycled collection for Tesco will be launched, that has been designed by Nin. Ruth Ferguson is the Founder and Creative Director of Olga Olsson, an award-winning luxury ethical fashion brand that works with small producers in Brazil to create high-end swimwear collections.
Prior to Olga Olsson Ruth spent six years in the mainstream fashion industry, working on design, product development and quality management for both luxury and high street brands, including Matthew Williamson, Hackett, Alexander Mcqueen, River Island, Principles, and Harrods. Ruth combines technical knowledge of fabric and fits with experience on the ground with factories and producers in Latin America and Asia.
If you are interested in learning more about sourcing ethical production facilities and managing the development of your designs from inspiration to delivery, then Ruth is the person to talk to. Intellectual Property Rights e. Trade Marks and Design Rights. Joelson Wilson is alive to the issues which the ethical fashion industry faces, from sourcing materials to the production of garments and labelling.
Joanne can offer advice on the early development of your brand, including identifying, protecting and enforcing Intellectual Property rights and putting in place key agreements to exploit, enhance and manage your brand. Paul Chappe works alongside Joanne Gregory, offering advice on brand development, including identifying, protecting and enforcing Intellectual Property rights and putting in place key agreements to exploit, enhance and manage your brand.
Paul specialises in the specific needs of Start ups and entrepreneurs.